Oncological outcome of complete response after neoadjuvant chemotherapy for breast conserving surgery: a systematic review and meta-analysis
X Li, D Dai, B Chen, H Tang, W Wei - World journal of surgical oncology, 2017 - Springer
Background With limited sample sizes and single-institution designs, how complete
response (CR) after neoadjuvant chemotherapy (NAC) influences breast conserving surgery …
response (CR) after neoadjuvant chemotherapy (NAC) influences breast conserving surgery …
Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular …
R Chen, Y Ye, C Yang, Y Peng, B Zong, F Qu… - Breast cancer research …, 2018 - Springer
Purpose To assess the predictive role of pretreatment ki67 and Ki67 changes in breast
cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular …
cancer (BC) patients treated with neoadjuvant chemotherapy (NAC) in various molecular …
Exploring the effectiveness of molecular subtypes, biomarkers, and genetic variations as first-line treatment predictors in Asian breast cancer patients: a systematic …
NWS Bahrin, SNI Matusin, A Mustapa, LZ Huat… - Systematic …, 2024 - Springer
Background Breast cancer incidence has been on the rise significantly in the Asian
population, occurring at an earlier age and a later stage. The potential predictive value of …
population, occurring at an earlier age and a later stage. The potential predictive value of …
Present and changing trends in surgical modalities and neoadjuvant chemotherapy administration for female breast cancer in Beijing, China: A 10‐year (2006–2015) …
X Bao, K Sun, X Tian, Q Yin, M Jin, N Yu… - Thoracic …, 2018 - Wiley Online Library
Background This study was conducted to describe present and changing trends in surgical
modalities and neoadjuvant chemotherapy (NACT) in female breast cancer patients in …
modalities and neoadjuvant chemotherapy (NACT) in female breast cancer patients in …
Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 …
A Papakonstantinou, A Matikas, NO Bengtsson… - Cancer, 2020 - Wiley Online Library
Background Dose‐dense (DD) adjuvant chemotherapy improves outcomes in early breast
cancer (BC). However, there are no phase 3 randomized data to inform on its combination …
cancer (BC). However, there are no phase 3 randomized data to inform on its combination …
Is multifocal regression a risk factor for ipsilateral breast tumor recurrence in the modern era after neoadjuvant chemotherapy and breast conservation therapy?
DC Ling, PA Sutera, NA Iarrobino, EJ Diego… - International Journal of …, 2019 - Elsevier
Purpose Multifocal pattern of regression after neoadjuvant chemotherapy has been
identified as a risk factor for ipsilateral breast tumor recurrence (IBTR). We aimed to …
identified as a risk factor for ipsilateral breast tumor recurrence (IBTR). We aimed to …
Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review and meta-analysis spanning four decades
Abstract In Southeast Asia, breast cancer is the most prevalent cancer among women and
ranks as the second leading cause of cancer-related deaths. This systematic review and …
ranks as the second leading cause of cancer-related deaths. This systematic review and …
Association of plasma docetaxel levels with ABCB1 gene polymorphisms and tumour response in locally advanced breast cancer patients of South India on neo …
R Priyadarshini, GM Raj, R Sundaram, S Kayal… - Breast Cancer, 2021 - Springer
Background Genetic factors could be attributed to the variability in docetaxel plasma levels
and its subsequent therapeutic response. The objectives of this study were to assess the …
and its subsequent therapeutic response. The objectives of this study were to assess the …
Predictors of nodal pathological complete response in Asian women with stage II–III node-positive breast cancer
G Montagna, Y Tong, M Ritter, J Levi, WP Weber… - Oncology, 2021 - karger.com
Background: Neoadjuvant chemotherapy (NAC) is increasingly used to treat node-positive
(N+) breast cancer. Predictors of nodal pathological complete response (pCR) in Asian …
(N+) breast cancer. Predictors of nodal pathological complete response (pCR) in Asian …
[HTML][HTML] Assessment of Predictive Factors for Response to Neoadjuvant Chemotherapy in Breast Cancer
Y Bachheti, V Nautiyal, M Ahmad - Asian Journal of Oncology, 2023 - asjo.in
Objectives The early identification of breast cancer patients who will not respond to
neoadjuvant chemotherapy is valuable for timely change in management strategies …
neoadjuvant chemotherapy is valuable for timely change in management strategies …